2020-2027 Analysis and Review Bacillary Dysentery Drugs Market

Bacillary Dysentery Drugs Market

Bacillary Dysentery Drugs Market By Drug Class (Beta Lactams, Quinolones, Macrolides and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

13-06-2020 REP-HC-5115 40 Tables 120 pages Format

The bacillary dysentery drugs market was valued at USD 1,291.8 Mn by 2019. The rising prevalence of bacillary dysentery infections in the developing regions of the world primarily drives the market growth. The furthermore looming threat of microbial resistance and effective implementation of treatment regimen will further bolster the bacillary dysentery drugs market growth.

Bacillary Dysentery Drugs Market

Bacillary dysentery is also popularly called as shigellosis, it still remains the cause of high mortality rate in the pediatric patients worldwide. It is basically a gram-negative non-motile bacillus microorganism belonging to the family Enterobacteriaceae present in 4 strains such as S. flexneri, S. dysenteriae, S. sonnei, S. dysenteriae etc.

The major segments related to the bacillary dysentery drugs market are: 

By Drug Class (2017–2027; US$ Mn)

Beta Lactams

Quinolones

Macrolides

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global bacillary dysentery drugs market
  • The overall segmentation of the bacillary dysentery drugs market, by drug class, distribution channel, and geography is minutely studied. Beta lactams and hospital pharmacy are dominating the drug class and distribution channel segments respectively
  • Rising prevalence of bacillary dysentery infection in the developing regions of the world
  • Effective implementation of treatment guidelines pertaining to bacillary dysentery and flourishing generic drugs market together accelerate the market growth

Report gist?

  • The study of the global bacillary dysentery drugs market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers a qualitative and quantitative analysis of the overall market segmented on the basis of drug class and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of bacillary dysentery drugs due to the significant increase in the number of people suffering from bacillary dysentery in the developing regions of the world
  • The report will benefit physicians engaged in the implementation of treatment regimen for bacillary dysentery infection worldwide
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to bacillary dysentery drugs market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Beta lactams are representing the largest market share in the drug class segment for the bacillary dysentery drugs market. It is always prescribed in combination with either penicillin or cephalosporin to increase its bactericidal spectrum of activity against microorganisms responsible for the occurrence of bacillary dysentery. It is the first-line therapy drug and is prescribed for 5 days to decrease the concentration of Shiga toxin (Stx) concentrations in the stool and thereby accelerates the elimination of Shigella and the subsequent spread of infection. Quinolones are ready to showcase exemplary market growth performance during the forecast period on account of low microbial resistance observed against ciprofloxacin and clinical studies have confirmed its broad-spectrum activity against all the strains of Shigella strains.

Hospital pharmacy is currently dominating the distribution channel segment for the bacillary dysentery drugs market. Dispensing of antibiotics varies as per the treatment regimen adopted by physicians in different parts of the globe hence precise compounding by hospital pharmacists is inevitable to negate the occurrence of drug-related adverse events. Retail pharmacy is expected to register comfortable market growth in the near future on account of the availability of cheap medicines due to government subsidy awarded for essential medicines and capacity to serve the medicinal requirements of patients residing in the remote locations.

The Asia Pacific is presently leading the geography segment for the bacillary dysentery drugs market. The rising prevalence of bacillary dysentery infection primarily drives the market growth in the region. As per the recent information provided by the National Institute of Health the annual incidence rate of bacillary dysentery in the South Asian countries is 13.2 per 1,000 individuals. Increasing urbanization, rising water and soil pollution, lack of civic amenities in the slum-dwelling together accentuate the market growth in the region. Europe is the second-largest regional segment on account of the effective implementation of treatment guidelines pertaining to bacillary dysentery treatment as sanctioned by the European Medical Agency (EMA) for the region. North America is anticipated to be the fastest-growing regional segment for the bacillary dysentery drugs market. Affordable reimbursement scenario and developed healthcare infrastructure together accentuate the market growth in the region.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.